March 01, 2021
Weil is advising Charles River Laboratories on the antitrust aspects of its pending acquisition of Cognate BioServices, a leading cell and gene therapy contract development and manufacturing organization. The deal, currently valued at $875 million, will position Charles River as a leading scientific partner in cell and gene therapy. Charles River first announced the deal on February 17, 2021 and expects to close by the end of the first quarter.
Weil’s Antitrust team is led by of global Antitrust/Competition practice Head Steven Newborn and partners Brianne Kucerik and Vadim Brusser (in Washington, D.C.), and includes counsel Nafees Saeed (London) and associates Kristin Sanford and Alexandra Ampudia (Washington, D.C.).